CS（SM+CGL）
Contact Us →CS is a synergistic peptide combination of Cagrilintide and Semaglutide. It has attracted growing interest in research focused on weight loss, metabolic health, and appetite regulation.
Studies have shown that Cagrilintide, a long-acting amylin analogue, reduces appetite and slows gastric emptying, while Semaglutide, a GLP-1 receptor agonist, enhances glucose-dependent insulin secretion and promotes satiety. Together, they offer complementary mechanisms for superior body weight reduction and glycemic control. This combination may also play a role in metabolic syndrome management, obesity treatment, and improvement of cardiovascular risk factors.
Key Research Areas:
-
Dual amylin/GLP-1 agonism and appetite suppression
-
Body weight reduction and obesity research
-
Glucose homeostasis and type 2 diabetes management
-
Gastric emptying modulation and satiety enhancement
-
Metabolic syndrome and cardiovascular risk reduction
